Pharmaceuticals company Piramal Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 was Rs 2,754 crore, an increase of 8% compared to Rs 2,552 crore in Q4FY24. EBITDA grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiatives EBITDA for Q4FY25 was Rs 603 crore, an increase of 8% compared to Rs 556 crore in Q4FY24. The EBITDA Margin was 22% in both Q4FY25 and Q4FY24. PAT (before exceptional item) for Q4FY25 was Rs 154 crore, an increase of 16% compared to Rs 132 crore in Q4FY24. PAT (after exceptional item) for Q4FY25 was Rs 154 crore, a significant increase of 52% compared to Rs 101 crore in Q4FY24. FY25 Financial Highlights: Revenue from Operations for FY25 was Rs 9,151 crore, an increase of 12% compared to Rs 8,171 crore in FY24. EBITDA for FY25 was Rs 1,580 crore, an increase of 15% compared to Rs 1,372 crore in FY24. The EBITDA Margin was 17% in both FY25 and FY24. PAT (before exceptional item) for FY25 was Rs 91 crore, an increase of 13% compared to Rs 81 crore in FY24. PAT (after exceptional item) for FY25 was Rs 91 crore, a substantial increase of 411% compared to Rs 18 crore in FY24. Nandini Piramal, Chairperson, Piramal Pharma said, “FY25 has been a steady year for the company as we crossed USD 1 billion in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business. We believe, we are on track to deliver on our FY2030 aspirations of becoming a USD 2 billion revenue company with 25% EBITDA margins and high teens ROCE.” Result PDF
Conference Call with Piramal Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Piramal Pharma announced Q3FY25 results Revenue from Operations: Rs 2,204 crore, up 13% YoY from Rs 1,959 crore CDMO: Rs 1,278 crore, up 13% YoY from Rs 1,134 crore CHG: Rs 654 crore, up 14% YoY from Rs 576 crore ICH: Rs 278 crore, up 10% YoY from Rs 252 crore EBITDA: Rs 350 crore, up 6% YoY from Rs 330 crore EBITDA Margin: 16%, down 1% YoY from 17% Share of Net Profit of Associates: Rs 17 crore, up 22% YoY from Rs 14 crore Net Profit After Tax: Rs 4 crore, down 64% YoY from Rs 10 crore Nandini Piramal, Chairperson, Piramal Pharma, said: “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth. The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.” Result PDF